FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...
The European Medicines Agency has recommended granting marketing authorization for a new hybrid formulation of buprenorphine as a substitution treatment of opioid drug dependence. Buprenorphine ...
Format Comparison for Needle-Free GLP-1 Options, Administration Preferences, and Telehealth Access PathwaysHOUSTON, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational ...
The proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation in form of orally dispersible films allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, ...
Please provide your email address to receive an email when new articles are posted on . Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a ...
Awakn Life Sciences (OTC:AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global licensing agreement ...
Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin’s effect on platelet ...
Patients with alopecia areata showed improved response rate with oral Janus kinase (JAK) inhibitors vs topical and sublingual JAK inhibitor administration. Oral administration of Janus kinase (JAK) ...
Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...
VANCOUVER, BC / ACCESS Newswire / July 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback